Our parent company, 22nd Century Group, Inc. is a plant biotechnology company with an important mission: To Reduce the Harm Caused by Smoking.
Our proprietary genetic engineering technology and plant breeding expertise allow us to regulate the level of nicotine (and other nicotinic alkaloids) in the tobacco plant. As a result of our unique technology, we are able to grow tobacco with up to 97% less nicotine than conventional tobacco – as well as plants with relatively high nicotine levels. The applications for this technology are extraordinary; in independent clinical studies, our Very Low Nicotine (VLN) tobacco has demonstrated remarkable efficacy as a smoking cessation aid. On the other hand, for smokers who do not wish to quit, our high nicotine tobacco enables us to produce a cigarette with what we believe is the world’s lowest tar-to-nicotine ratio.
We have an extensive intellectual property portfolio of issued patents and patent applications relating to the tobacco plant. Our technology has created, and will continue to develop, a pipeline of products. We are focused on the following smoking harm reduction initiatives:
- The research and development of potentially reduced-exposure or Modified Risk Tobacco Products
- The development of X-22, a prescription-based smoking cessation aid consisting of Very Low Nicotine cigarettes
- The production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA)
Visit xxiicentury.com for more info.
22nd Century Group, Inc. | NYSE MKT: XXII